MVA.HIVconsv

BIOLOGICAL3 trials

Sponsors

University of Oxford

Conditions

AIDSHIV InfectionHIV-1 InfectionsHepatitis C Infection

Phase 1

Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults

CompletedNCT01151319

University of OxfordHIV-1 Infections

Start: 2010-10-31End: 2014-04-30Updated: 2014-04-30

Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults

CompletedNCT02099994

University of OxfordAIDS

Start: 2014-03-31End: 2015-08-31Updated: 2016-05-30

A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination

CompletedNCT02362217

University of OxfordHepatitis C Infection, HIV Infection

Start: 2014-10-31End: 2017-10-31Updated: 2018-10-11

Related Papers

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection

Frontiers in Immunology2019-01-1837 citations

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens

PLoS ONE2017-07-1820 citations

Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines

PLoS ONE2017-04-2730 citations

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults

PLoS ONE2015-08-0743 citations

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

PLoS ONE2014-07-0972 citations